30 November 2005 in Journal of Neuroscience
Amyloid-β (Aβ) has been implicated in memory loss and disruption of synaptic plasticity observed in early-stage Alzheimer's disease. Recently, it has been shown that soluble Aβ oligomers target synapses in cultured rat hippocampal neurons, suggesting a direct role of Aβ in the regulation of synaptic structure and function. Postsynaptic density-95 (PSD-95) is a postsynaptic scaffolding protein that plays a critical role in synaptic plasticity and the stabilization of AMPA (AMPARs) and NMDA (NMDARs) receptors at synapses. Here, we show that exposure of cultured cortical neurons to soluble oligomers of Aβ1-40reduces PSD-95 protein levels in a dose- and time-dependent manner and that the Aβ11-40-dependent decrease in PSD-95 requires NMDAR activity. We also show that the decrease in PSD-95 requires cyclin-dependent kinase 5 activity and involves the proteasome pathway. Immunostaining analysis of cortical cultured neurons revealed that Aβ treatment induces concomitant decreases in PSD-95 at synapses and in the surface expression of the AMPAR glutamate receptor subunit 2. Together, these data suggest a novel pathway by which Aβ triggers synaptic dysfunction, namely, by altering the molecular composition of glutamatergic synapses.
17 December 2019 in Annals of Neurology
FGfor the LIPCAL‐ALS Study Group
for the LIPCAL‐ALS Study Group
+16
6 June 2018 in The EMBO Journal
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
1 March 2002 in Archives of Neurology
Research from JAMA Neurology — Botulinum Toxin A Treatment for Primary Hemifacial Spasm — A 10-Year Multicenter Study